< Back

PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections

Jun 23, 2022 at 10:00 AM EDT

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webinar on the cost of managing surgical site infections (“SSIs”) on Thursday, June 23, 2022, at 10:00 AM Eastern Time.

The webinar will feature presentations from KOLs Kyle Cologne, M.D., Los Angeles County General – USC Medical Center, who will provide a general-hospital perspective on the cost of managing SSIs, and Elliot Goodman, M.D., Mount Sinai Health System, who will discuss the impact SSIs have on quality measures and performance from an integrated delivery network (IDN) perspective.

The PolyPid leadership team will provide a corporate update, including a discussion on the timing of the topline results following the recent completion of patient enrollment in the SHIELD I Phase 3 study of D-PLEX100 for the prevention of SSIs in abdominal surgery.

A question and answer session will follow. To register for the event, please click here.

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >